Agios Pharmaceuticals | AGIO - Net Income


Agios Pharmaceuticals reported $-103.43M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 186M 752M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD -23.75M 151.49M Sep/2025
Astellas Pharma JPY 79.21B 10.79B Sep/2025
AstraZeneca USD 2.53B 83M Sep/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 5.58B 78M Sep/2025
Exelixis USD 193.58M 8.73M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
GlaxoSmithKline GBP 2.01B 570M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025